Ezetimibe. Market analysis

Nature Reviews Drug Discovery

Volumn 2, Issue 2, 2003, Pages 97-98

  Earl, John ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Intl   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMPLITAPIDE; NICOTINIC ACID; PLACEBO; PROBUCOL; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE;

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MONOTHERAPY; NOTE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ARTICLE; BLOOD; CHEMISTRY; DRUG COMBINATION; METABOLISM;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037315953     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1015     Document Type: Note

References (7)

1. Executive summary of the third report of the national cholesterol education program (NCEP) expert on detection, evaluation and treatment of high blood cholesterol (adult treatment panel III). JAMA 285, 2486-2497 (2001).
2. Burnett, D. A., Caplen, M. A., Davis, H. R. Jr, Burrier, R. E. & Clader, J. W. 2-azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. 37, 1733-1736 (1994).
3. Clader, J. W. et al. 2-azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus. J. Med. Chem. 39, 3684-3693 (1996).
4. Van Heek, M. A. et al. In vivo metabolism-based discovery of a potent cholesterol inhibitor, SCH 58235, in the rat and rhesus monkey through identification of the active metabolites of SCH 48461. J. Pharmacol. Exp. Therapeut. 283, 157-163 (1997).
5. Rosenblum, S. B. et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-4S- (4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41, 973-980 (1998).
6. FDA Drug Approvals List [online] (cited 6 Jan 2003) http://www.fda.gov/cder/foi/label/2002/21445lbl.pdf
7. Wu, G., Wong, Y., Chen, X. & Ding, Z. A novel one-step diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors. J. Org. Chem. 64, 3714-3718 (1999).